Recombinant multi-species RAP1A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine RAP1A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the Ras family of small GTPases. The encoded protein undergoes a change in conformational state and activity, depending on whether it is bound to GTP or GDP. This protein is activated by several types of guanine nucleotide exchange factors (GEFs), and inactivated by two groups of GTPase-activating proteins (GAPs). The activation status of the encoded protein is therefore affected by the balance of intracellular levels of GEFs and GAPs. The encoded protein regulates signaling pathways that affect cell proliferation and adhesion, and may play a role in tumor malignancy. Pseudogenes of this gene have been defined on chromosomes 14 and 17. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]
The Alternative Names of target: C21KG,G-22K,GTP-binding protein smg p21A,KREV-1,KREV1,Krev-1,RAP-1A,RAP1,RAP1A,Rap1,Rap1a,Ras-related protein Krev-1,Ras-related protein Rap-1A,SMGP21,rap 1A

Target products collectionGo to RAP1A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP10848-Ag-1/ GM-Tg-hg-IP10848-Ag-2 Human RAP1A protein Human
GM-Tg-rg-IP10848-Ag-1/ GM-Tg-rg-IP10848-Ag-2 Rat RAP1A protein Rat
GM-Tg-mg-IP10848-Ag-1/ GM-Tg-mg-IP10848-Ag-2 Mouse RAP1A protein Mouse
GM-Tg-cynog-IP10848-Ag-1/ GM-Tg-cynog-IP10848-Ag-2 Cynomolgus/Rhesus macaque RAP1A protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP10848-Ag-1/ GM-Tg-felg-IP10848-Ag-2 Feline RAP1A protein Feline
GM-Tg-cang-IP10848-Ag-1/ GM-Tg-cang-IP10848-Ag-2 Canine RAP1A protein Canine
GM-Tg-bovg-IP10848-Ag-1/ GM-Tg-bovg-IP10848-Ag-2 Bovine RAP1A protein Bovine
GM-Tg-equg-IP10848-Ag-1/ GM-Tg-equg-IP10848-Ag-2 Equine RAP1A protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP10848-Ag-1/ GM-Tg-hg-IP10848-Ag-2; GM-Tg-rg-IP10848-Ag-1/ GM-Tg-rg-IP10848-Ag-2;
GM-Tg-mg-IP10848-Ag-1/ GM-Tg-mg-IP10848-Ag-2; GM-Tg-cynog-IP10848-Ag-1/ GM-Tg-cynog-IP10848-Ag-2;
GM-Tg-felg-IP10848-Ag-1/ GM-Tg-felg-IP10848-Ag-2; GM-Tg-cang-IP10848-Ag-1/ GM-Tg-cang-IP10848-Ag-2;
GM-Tg-bovg-IP10848-Ag-1/ GM-Tg-bovg-IP10848-Ag-2; GM-Tg-equg-IP10848-Ag-1/ GM-Tg-equg-IP10848-Ag-2
Products Name RAP1A protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name RAP1A
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine RAP1A protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.